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ABSTRACT
Chronic pulmonary hypoxia commonly results in the sustained expression of HIF1
(hypoxia inducible factor 1), a heterodimeric transcription factor, that, if unrestrained, can
result in dramatic vasculature remodeling, pulmonary arterial hypertension, and rightsided heart failure. Together, these pulmonary disorders cost approximately $100 billion
annually to treat due to the limited therapeutic targets designed to inhibit HIF1 expression.
In this study, we introduce a translational regulator of HIF1 expression, known as
Cytosolic polyadenylation element binding proteins 2 (CPEB2). Our lab has previously
demonstrated in cancer cells that alternatively spliced isoforms of CPEB2 regulate the
translation of the HIF1 oxygen-dependent subunit, HIF1α, in opposing fashions: the
CPEB2A isoform represses its translation, while the CPEB2B isoform activates its
translation. Although it is well established that during hypoxia, HIF1α levels are initially
upregulated due to a decrease in proteasomal degradation, we hypothesized that during
prolonged, or chronic, hypoxia, the expression of HIF1α is maintained through a stressinduced translational mechanism, likely alongside a decrease in proteolytic activity meant
to stabilize HIF1α protein. Here we demonstrate that targeting the CPEB2B splice isoform
inhibited the translation of nascent HIF1α protein during chronic hypoxia. Moreover, we
characterized how CPEB2A and B expression impacts vasculature remodeling in a 3D
angiogenic cell model. These findings provide evidence that this splicing event could act
as a therapeutic target for treating chronic hypoxia-related pulmonary diseases and
diseases that present with dysregulated HIF1 expression.

v

CHAPTER ONE
INTRODUCTION

Oxygen Homeostasis
Oxygen (O2) plays a vital role in life as we know it. Not only is it needed for
respiration, but O2 is also a crucial component for the development, growth and
preservation of our tissue’s structural integrity (1). It is also one of the main components
needed to generate ATP (2). Even so, O2 poses a danger to life if not properly regulated
(3). In order to both generate ATP and perform cellular respiration; a series of redox
reactions must take place within the cell’s mitochondria through a process known as
oxygen phosphorylation (4,5). It is within the final stages of these reactions that O2
molecules are utilized to accept incoming electrons needed for ATP production, ultimately
causing O2 to split and form water biproducts alongside toxic elements known as free
radicals, and reactive oxygen species (ROS), such as OH- or H2O2 (5,6). If allowed to
persist, or accumulate, these elements can cause serious cellular damage (e.g., nucleic
acid oxidation, lipid peroxidation, protein denaturation, cellular senescence) (6,10,11).
Long term, this damage can present itself in the form of cancer, early-aging, and heart
disease. (8,9) Fortunately, eukaryotes have adapted responses that act to keep free
radicals and ROS from accumulating and causing lifelong harm. This is primarily
accomplished by the production of antioxidants (7) but ensuring that O2 levels remain
within an appropriate range is also important. Our cells need to prepared, should O2 levels
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rise, or become hyperoxic (10-12). In case this occurs, having a mechanism that can
regulate O2 levels, before they have a chance to produce toxic bi-products, is crucial.
Likewise, when oxygen levels are limited, or hypoxic, our cells need an orchestrated
response return to oxygen homeostasis.

Hypoxia
Normoxia is considered the oxygen level at which physiological activity can
proceed as normal. Hence, hypoxia is a state of lower-than-normal oxygen levels,
implying an imbalance between oxygen supply and demand (12). The threshold between
normoxic and hypoxic conditions varies from tissue to tissue. For example, 3-9% oxygen
level is considered normal for most organs, compared to the air, which has an oxygen
makeup of around 20% (13, 14). When levels fall below 1%, studies suggest ATP
biogenesis begins to slow, which consequently leads to the inhibition of energyconsuming cellular processes in order to save energy for processes that help the cell find
new oxygen (e.g., via angiogenesis) (15,16), or produce new ATP (e.g., through
converting glucose to pyruvate (17).

Hypoxic Responses (acute vs chronic)
On an organismal scale, hypoxia has a massive effect on the pulmonary system.
There are several conditions, including environmental factors and disease, that can cause
hypoxia. For example, a severe asthma attack can narrow the airways to such an extent
that it temporarily induces hypoxia (acute hypoxia). If treated, oxygen levels will return to
normal without any serious reparations. However more diffuse and long-term causes of
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hypoxia, such as smoking cigarettes, pollution, high altitudes, sleep apnea, pulmonary
diseases (e.g., cystic fibrosis, and cancer) and injury can lead to permanent changes to
the pulmonary system. These permanent changes associated with chronic hypoxia are
caused by the overexpression of and signaling by mitogens that initiate endothelial and
smooth muscle cell proliferation, vascular remodeling, airway constriction, and elevated
blood pressure (18). In a healthy individual, pulmonary arterial blood pressure is normally
25/10 mm Hg (19). If this pressure exceeds 40/20 mm Hg, then the patient is considered
to have pulmonary arterial hypertension (PAH) (19,20).

In the United States, PAH

currently has an incidence rate of 378 per 100,000, resulting in approximately 200,000
hospital visits and 500-1000 new US cases per year (18). Treatment for these conditions
has been limited to vasodilators and oral medications, alongside hospital stays that
currently cost the United States over 100 billion dollars per year to manage (19).
Moreover, without the appropriate intervention, PAH can cause sustained pressure load
on the right ventricle of the heart, leading to hypertrophy and eventual right-sided heart
failure (21,22). For that reason, targeting the symptoms at the source could potentially
alleviate treatment and hospital costs, as well as improve the morbidity associated with
chronic hypoxia. For example, through the inhibition of the overexpressed mitogens
detected during hypoxia, identified as hypoxia stress response proteins.

Hypoxic Stress Response (HSR)
Physiological stress can be defined as any condition that challenges the
homeostasis of a cell or an organism. When the homeostasis is challenged, as is the case
in hypoxia, an organism will react by initiating a stress response that will induce a cascade
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of signaling that serves to either defend or destruct the cell. The fate of the cell is
determined by several factors, such as cell type, amount of stress, and type of stress.
The hypoxic stress response normally serves to upregulate mRNA transcripts that will
defend pulmonary cells from oxygen limitations, and return the entire system to
homeostasis. To match O2 supply with biological demands, one of the main goals of the
hypoxic stress response in the pulmonary system is to force oxygenated blood to areas
that need it most. This requires a series of cell signaling to rapidly constrict the pulmonary
arteries and increase overall pressure. If oxygen levels return to normal in an appropriate
span of time, this response does not lead to irreparable damage. However, as hypoxic
conditions progress, the original solution can become a problem. As mentioned
previously, the requirement for continuous vasoconstriction and heightened blood
pressure means that the heart needs to work at an accelerated pace, which can ultimately
lead to heart failure. Therefore, closer examination into the innerworkings of the HSR may
allow physicians to better treat patients experiencing conditions related to hypoxic stress.

HIF proteins
The HSR cascade of cell signaling is initiated through a family of proteins known
as hypoxia inducible factors (HIFs) (23). This class of proteins made up of HIF1, HIF2
and HIF3, are αβ-heterodimeric transcriptional activators that bind to a hypoxic response
element (HRE) consensus sequence 5′-ACGTG-3′ in the promoter of hypoxia-related
DNA targets. This binding occurs via highly conserved N- and C-terminal transactivation
domains (N-TAD and C-TAD) present on HIF1/2 (24). The HIF1/2 proteins consist of an
oxygen-dependent alpha subunit, and continuously expressed beta subunit, that, upon

4

dimerization in the nucleus, activate transcription of genes. Previous studies recognize
that HIF1 and HIF2 are both present in all cell types, although their target genes,
activation level within each cell type, and timing of activation, all vary between the two
family members (25, 26). HIF3 on the other hand, remains understudied and its role as a
transcription factor is elusive (27). HIF1/2 transcriptional activation ultimately leads to
hypoxia-induced cellular and vascular remodeling responses, such as new blood vessel
growth (angiogenesis), cell proliferation, cell migration, and increased vascular
permeability through the onset of HIF target genes (28).

HIF1α Protein Stabilization Following Hypoxia
HIF1/2 transcription factors are composed of two subunits: the oxygen-dependent
alpha subunit, and the constitutively expressed beta subunit. Under normoxia, both
subunits are continuously synthesized. However, HIF1/2α contains an oxygen dependent
domain (ODD) with conserved proline residues (P402 and 564) that are quickly
hydroxylated by prolyl hydroxylase enzymes (PHD) (30). In turn, the newly hydroxylated
alpha-subunit is recognized by the Von-Hippel Londau (VHL)-containing E3 ligase
complex for ubiquitination. Ubiquitination, or “the kiss of death,” is the preliminary step in
targeting a protein for proteasomal degradation. Like many substrates, HIF1/2α are
targeted through the covalent binding of ubiquitin protein, catalyzed by a cascade of
transferase enzyme interactions: E1

E2

E3, with E3 being the crucial component

for substrate-targeting (31). The primary target of the VHL- E3 complex is HIF1α, thus,
when VHL targets HIF1α, the consequential assembly of a polyubiquitin chain leads to
the capture of HIF1α and its degradation by an abundant complex of proteases known as
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the proteosome (32). Thus, when the oxygen-dependent domain of HIF1/2α is
hydroxylated, as is the case under normoxic conditions, this alpha subunit is quickly
degraded as a means to inhibit the dimerization of HIF1α and HIFb and halt the activation
of hypoxic stress genes. When the cell encounters hypoxic stress, however, the PHD
enzymes needed to hydroxylate the alpha subunit cannot mark it for ubiquitination,
resulting in the stabilization of the alpha subunit (33). Once the alpha subunit is stabilized,
it can translocate to the nucleus where it will dimerize with the beta subunit and proceed
with transcription of downstream target genes containing a hypoxia response element
(HRE) in their promoter region (33).

The Role of HIF in Pulmonary Hypoxia
HIF transcription is responsible for the activation of over 100 different genes
involved in cellular and vascular remodeling responses, including new blood vessel
growth, cell proliferation, cell migration, and increased vascular permeability (34). One
such target gene is vascular endothelial growth factor, VEGF. VEGF is a direct
transcriptional target of HIF1 and mitogen responsible for new blood vessel growth
through capillary branching (e.g., angiogenesis) (35). When oxygen is scarce, growth
factors respond by generating new blood vessel sprouts that enable the delivery of
oxygen and nutrients to the body's tissues. As one of the most remarkable angiogenic
growth factors, VEGF activates capillary sprouting through binding to two tyrosine kinase
receptors (VEGF-R): VEGF-R1 and VEGF-R2 on the surface of vascular endothelial cells
(36,37). When bound to VEGFR1, its kinase activity leads to increased expression of
proteins that will degrade the extracellular matrix and promote cell migration to pave the
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way for new capillary branches off from existing blood vessels (36,37). Binding and
activation of VEGFR2 produce platelet-activating factors that promote cell proliferation
and migration, in addition to increasing vascular permeability (36,37). Previous studies,
using either heterozygous VEGF (+/-), VEGF-R1 (+/-), or VEGF-R2 (+/-) knockout mice,
all revealed embryonic lethality resulting from defects in vascular formation, indicating the
importance of both VEGF and its receptors for endogenous blood vessel formation, and
new growth under hypoxic conditions (38).

Global and Hypoxic-Induced Protein Synthesis
Following transcription, messenger RNA (mRNA) is processed to add a modified
guanine, or “cap,” to the 5’ untranslated region (UTR) and to add a polyadenylated (AAA)
tail to the 3’UTR. The 5’ cap acts as the entry point of the mRNA into the ribosome, that,
alongside eukaryotic initiation factors (eIFs), will initiate the mRNA’s translation into
nascent protein. The ribosome contains two subunits: 40s and 60s. At the start of
translation and through the interactions with eIF1-3, the 40s ribosomal subunit can bind
to the initiating tRNA and GTP to form the 43s pre-initiating complex (PIC) that is then
recruited to the 5’ cap of the mRNA via the eIF4 complex (39). In addition to PIC and
eIF4, another protein known as PABP (poly-A-binding protein) will bind to both the
polyadenylated tail in the 3’ UTR of the mRNA, and to eIF4g on the mRNA 5’ cap,
consequently circularizing the mRNA into what is known as the 48s complex (40,41). The
initiating tRNA then scans and locates the mRNA’s start codon, leading to the removal of
all initiation factors from the complex, via GTP hydrolysis. The larger ribosomal subunit,
60s, joins the 40s subunit to initiate translation of mRNA into a polypeptide chain (40-42).
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Once the tRNA has delivered the corresponding amino acids, release factors bind to the
stop codon in the mRNA, cleaving the bond between the polypeptide sequence and the
tRNA, in turn forming a nascent protein (40-42).
Translation requires the consumption of an enormous amount of energy, and
without oxygen, a general suppression of energy-exhausting processes, including the
global translation of proteins, is observed (43) . Human cells do, however, manage to
synthesize essential proteins needed to adapt to hypoxic conditions. Some studies have
suggested that under certain environmental stresses like that of hypoxia, perturbations in
normal translation can lead to the formation of mRNA triage sites known as stress
granules (SG) (44,45). These granules consist of stalled translation initiation complexes
and normal mRNA processing elements that are ready to take on ancillary emergency
function as the stressor ensues (44,45). Untranslated mRNA coding for proteins that are
required to respond to the stress are subsequently routed to the SG to await their
translational fate (46-49). Additionally, it has been suggested that most protein translation
modulations are observed during the first stage of translation: the initiation step (42,63).
Otherwise, the ribosome risks producing an incomplete and incompetent protein (50).
This could indicate a role for eukaryotic initiation factors in helping to maintain the
translation of hypoxic stress response elements (e.g., HIF1α) as hypoxia progresses.
Eukaryotic initiation factors (eIFs) are also commonly found to be overexpressed in
tumors exhibiting strong hypoxic cores, and their expression has been correlated with
increased translation of stress-induced proteins, like HIF1, which is a key factor in tumor
survival (50). Lastly, some literature suggests that, in addition to its stabilization, HIF1α
may be specially translated during hypoxia by RNA binding proteins (RBP’s) that regulate
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post-transcriptional polyadenylation (52-55). These RBPs are known more specifically as
cytoplasmic polyadenylation element binding proteins (CPEB). One such family member,
CPEB2, has even been detected in stress granules following the induction of stress, and
could thus be involved in the complex that helps to maintain HIF1 expression during
chronic hypoxia (44).

CPEB proteins
Cytoplasmic Polyadenylation Element Binding proteins are sequence-specific
RNA binding proteins that control translation in development and disease (54-56). A
number of estimates suggest that between 20-40% of mammals, including humans, are
subject to translational regulation by CPEB proteins, although CPEB homologs have been
identified in a number of different species (57-58). For example, the first member of the
CPEB family, CPEB1, was originally discovered in Xenopus laevis (African clawed frog)
by Hake and Richter in 1994. These labs determined that a number of mRNAs are stored
dormant in oocytes until their subsequent use during later stages of meiosis, when they
are “unmasked” by CPEB proteins (42, 59). It is now evident that invertebrates also
contain genes of the CPEB family, albeit only two of the members, compared to the four
CPEB family members in vertebrates (42). All vertebral members are defined by the
presence of specific domains that allow for their RNA binding, specificity, and cytosolic
polyadenylation, including an unstructured N-terminal region with no obvious conserved
function, followed by two RNA-recognition motifs (RRM) and lastly a zinc-finger-like motif
at the carboxy end (58,60,61). In spite of these conserved regions, each family member
appears to have their own specific mRNA target and expression among different tissues,
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indicating likely differences in the role each CPEB protein plays in development
(58,60,61). For the significance of this study, one example of familial variation among
CPEB proteins has been made evident in CPEB2, which has been assessed for its
specificity to the 3’ end untranslated region (3’UTR) of HIF1α mRNA.

CPEB translational regulation
How much protein each mRNA molecular will produce at any given moment is
highly controlled across eukaryotic species (57). The RNA-binding elements that normally
control these processes often reside within the 3’UTR which interacts with a complex of
sophisticated proteins to regulate mRNA translation (57). Previous work by both the
Mendez and Richter labs has revealed that CPEB proteins recognize and bind to a
consensus site in the 3’UTR of specific mRNA, thereby regulating 3’UTR polyadenylation
and thus, mRNA translation (62). In brief, it was discovered that oocytes of all animals
contain dormant mRNA with short poly(A) tails of around 20-40 nucleotides (42, 62).
Following fertilization these mRNA become activated, but only after the elongation of their
poly(A) tail through a process known as polyadenylation. Normally, mRNA is cleaved 2030 nucleotides downstream of a AAUAAA hexanucleotide sequence on the C-terminus
and polyadenylated in the nucleus, where it will obtain a poly(A) tail averaging 200-250
nucleotides in length. However, mRNA that contains a CPE site downstream of that
hexonucleotide sequence will be recognized in the cytoplasm by CPEB and several
associated factors, consequently removing most of the target mRNA poly(A) and
rendering the mRNA as dormant (61).
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To date, four CPEB proteins have been identified, although CPEB1, discovered
originally by the Richter and Mendez laboratories, has been the most extensively
characterized. From their research, the regulatory protein complex that CPEB1 proteins
interacts with in order to control the translation of its mRNA targets has been identified.
One such protein associated with CPEB1 is Maskin, which, when recruited by CPEB1,
can bind to eIF4E (cap-binding protein) and compete with eIF4G (modular scaffold
protein) binding to the same region (42). As a result, eIF4G cannot modulate 40s
ribosomal recruitment to the mRNA cap for translational initiation (42,62). In other words,
when Maskin associates with CPEB1 near the 3’UTR CPE site on the mRNA, Maskin will
bind to eIF4E and indirectly block translation. However, if the mRNA’s poly(A) is
elongated, eIF4G will facilitate PABP recruitment to the complex and displace Maskin
from eIF4E so that translation can ensue.
Another protein that has been analyzed for its association with CPEB1 is the
cleavage and polyadenylation specificity factor, CPSF, which aids in CPEB-instigated
polyadenylation (42,62). When stabilized by CPEB1, CPSF can bind to the AAUAAA
hexanucleotide sequence upstream of the CPE site and recruit poly(A) polymerase to the
end of the mRNA (42,62). Therefore, CPEB family members are capable of repressing
translation by indirectly interrupting the 40s ribosomal subunit’s recruitment and
subsequent translational initiation and can induce translation by promoting poly(A)
elongation. Although the associated factors involved in translation control via CPEB2-4
family members are more elusive than those determined to associate with CPEB1,
previous studies have revealed the interaction between CPEB2-4 and both eukaryotic
translational initiation (eIFs) and elongation factors (eEFs) (42,62-65).
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Constitutive and Alternative RNA Splicing
One of the most astounding findings in molecular biology was that eukaryotic
genes are discontinuous, with coding DNA being interrupted by stretches of non-coding
sequence (66). Prior to protein translation, nascent precursor mRNA is comprised of
introns, or non-coding sequence, interspersed between exons that code for the desired
protein of that transcript. As a fundamental step in gene expression, introns need to be
cut out, or spliced, from the final transcript while the exons are ligated together. This
process, which occurs in 95% of human genes (67), is performed by a ribonucleoprotein
(RNP) complex referred to as the spliceosome that accurately recognizes intended splice
sites (ss) in the pre-mRNA transcript, and cuts accordingly (68). Alongside the RNP
complex, splicing requires coordination with over three hundred associated proteins
(splicing factors) to help guide the spliceosome to the appropriate splice sites (66, 68,
69). A highly orchestrated series of events ultimately leads to a single intron’s removal,
followed by the fusion of the two surrounding exons to one another. In addition to
constitutive RNA splicing, the spliceosome and its associated splicing factors can
coordinate in a manner that allows for the alternative splicing of introns, and even exons,
from the final transcript. Alternative splicing allows for a single gene to produce multiple
mRNA transcripts to be translated into a multitude of proteins. In doing so, eukaryotes
experience vast diversity in protein expression, responses, and cellular localization (59,
70). Taken together, alternative splicing is an essential element in gene expression and
diversity among cellular responses and function (71).
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CPEB2 Splice Variants
Alternative splicing in CPEB proteins has been reported in at least three of the four
CPEB family members, including CPEB2 (72-75). In 2015, our lab published findings that
characterized a link between dysregulation in the ratio of two active CPEB2 splice
variants, CPEB2A and CPEB2B, and anoikis resistance in triple negative breast cancer
(54,55). Anoikis is a form of programmed cell death that a cell undergoes when it is
detached from its primary cell/extracellular attachment (75). If a cancer cell develops
anoikis resistance, its survival from dissociation can cause cancer metastasis, as is the
case in triple negative breast cancer (TNBC) (54, 55, 76-78). TNBC is an anomalous
subset of breast cancer characterized by the absence of typical chemotherapeutic
receptors (HER2, estrogen and progesterone) and exhibits a greatly reduced survival rate
as a result of its high metastatic rate (54,55). Our first indication of CPEB2 splice variants
was reported in 2015, when our lab used next generation RNA sequencing and The
Tumor Cancer Genoma Atlas (TCGA) to characterize the splicing events dysregulated in
TNBC. In brief, the control (non-cancer) samples exhibited a high CPEB2A/B ratio at
basal level, attributable to low endogenous CPEB2B expression versus high CPEB2A
expression. The CPEB2A/B ratio drops significantly by reason of an increase in the
expression of CPEB2B. Previously, CPEB2 splice variants were only characterized in
mouse hippocampus where the alternative splicing of CPEB2A and B in the presence of
a stress response, such as anoikis resistance, was not accounted for (79). Therefore,
what we found was that CPEB2A and B differ by the inclusion or exclusion of a single
exon, exon 3, that is differentially spliced out via its recognition by a splicing protein,
SRSF3 (serine-arginine rich splicing factor 3) that binds a consensus sequence in exon
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3. When bound, SRSF3 blocks the spliceosome from excluding exon 3 and, in turn, drives
the expression of CPEB2B (54,55). The exact mechanism behind how the inclusion of
exon 3 leads to the differences between CPEB2A and CPEB2B, and what the
endogenous role of CPEB2 A/B alternative splicing is in cellular responses, is still loosely
understood.

CPEB interactions with HIF1α
A number of publications over the last decade suggest that the role of CPEB2 is
to inhibit HIF1α translation. In fact, a publication by Chen and Huang labs in 2011
determined that the interaction between stress-responsive family member, CPEB2 (52),
and elongation factor eEF2 represses HIF1α mRNA translation under normal oxygen
levels (63), whereas during hypoxia, CPEB2-eEF2 dissociates from HIF1α, leading to its
rapid synthesis needed for hypoxia adaptation. Moreover, through polysomal profile
studies, Chen and Huang revealed that HIF1α RNA is available in polysomes in its
elongation phase, to readily translate HIF1α when hypoxia is encountered, and global
translation is inhibited. This finding further solidifies the hypothesis that HIF1α levels are
maintained during hypoxic exposure through a translational mechanism (63). Even more
notable, it reveals that the elongation phase of translation might be in part modulated by
the 3’UTR-bound CPEB2-eEF2 interaction (63). As previously mentioned, though,
published work by our lab has shown that CPEB2 has at least two splice variants that
play opposing roles in the regulation of HIF1α: CPEB2A inhibits HIF1α translation, while
CPEB2B enhances translation (54). Based on our published data on CPEB2, we reason
that Chen and Huang were only analyzing the CPEB2A splice variant and its interaction
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with eEF2 and the 3’UTR of HIF1α in its elongation phase under normoxia. Perhaps,
under hypoxia, CPEB2A dissociates, and CPEB2B binds to HIF1α to maintain HIF1α
during oxygen deficit.

Hypothesis and Specific Aims
The research presented in this thesis served to determine the mechanism by which
CPEB2 alternative splicing regulated HIF1α, and whether targeting CPEB2 alternative
splicing could be used to regulate the pulmonary changes that are commonly associated
with hypoxic disorders. To address these goals, we formulated two hypotheses. First, we
hypothesized that during chronic hypoxia, the expression of HIF1α is maintained through
a stress-induced translational mechanism, likely alongside an increase in HIF1α protein
stabilization (Figure 2). Second, we hypothesized that, since HIF1α is a master regulator
in hypoxia-induced pulmonary diseases, targeting its synthesis following chronic hypoxic
exposure could help alleviate pulmonary pathogenesis.
The aims of this thesis are two-fold. First, we aimed to delineate the role of CPEB2
alternative splicing in regulating HIF1α during chronic hypoxia. Second, we aimed to
determined whether targeting CPEB2 alternative splicing could be used to regulate VEGF
in a HIF1-dependent manner and in turn, regulate angiogenesis in a 3D vascular cell
model. This study suggested that CPEB2 A/S plays a critical role in maintaining HIF1a
expression during chronic hypoxia, and that this mechanism could be used as a target for
ameliorating vascular changes associated with hypoxia-induced pathologies (i.e.,
dysregulated angiogenesis).
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Figure 1. Central dogma for HIF1α stabilization during hypoxic exposure. In the presence
of oxygen, HIF is inactivated by posttranslational hydroxylation, via PHD enzymes, of
specific amino acid residues within its α subunits. Prolyl hydroxylation promotes
interaction with the von Hippel–Lindau protein (pVHL) E3 ubiquitin ligase complex and
proteolytic inactivation by proteasomal degradation. When hypoxic conditions are
encountered, PHDs can no longer hydroxylate HIF1α, therefore stabilizing the protein and
allowing it to translocate into the nucleus where it will dimerize with the beta subunit. As
a result, HIF1 will transactivate genes involved in the hypoxic stress response.
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Figure 2. Schematic representation of our central hypothesis. We hypothesized that,
during acute hypoxia, HIF1α protein is stabilized, however as chronic hypoxia ensues,
HIF1α translation is upregulated by a decrease in the CPEB2 A/B ratio via an increase in
the stress induced CPEB2B protein. Similarly, the CPEB2 binding partner and eukaryotic
initiation factor subunit, eiF3h is hypothesized to interact with and aid in promoting HIF1α
translation during chronic hypoxia.
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CHAPTER TWO
THE ROLE OF CPEB2 ALTERNATIVE SPLICING IN REGULATING HIF1α DURING
CHRONIC HYPOXIA

Abstract
The activation of HIF1 during hypoxia has long been recognized as a mechanism
regulated by the stabilization of the oxygen dependent HIF1α subunit that, when allowed
to accumulate, translocates to the nucleus and dimerizes with HIF1β to form HIF1. Acting
as a transcription factor, HIF1 then induces downstream hypoxia response genes to
combat hypoxic stress. However, as hypoxia persists chronically, eventually more HIF1α
protein will need to be synthesized to maintain HIF1 and the hypoxic stress response.
With the inhibition of global protein synthesis as a result of low O2, the cell needs to use
an alternative mechanism to produce supplemental HIF1α during chronic hypoxia.
Therefore, in this chapter, we utilize in vitro techniques to examine CPEB2B knockdown
and translational activity in vasculature endothelial and primary pulmonary cells paired
with hypoxic exposure. As a result, we revealed a novel role of CPEB2 A/S in regulating
the translation of HIF1α during the chronic hypoxic stress responses.

Introduction
We have previously published on the link between the deregulation of CPEB2 A/S
in triple negative breast cancer (TNBC), and an enhanced susceptibility to tumor
metastasis (54,55). In brief, our lab used next generation sequencing to identify
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dysregulated alternative splicing events in triple negative breast cancer cells that exhibit
a phenotype known as anoikis resistance: a key indicator of metastasis (54, 55). This
study revealed that: 1) a decrease in the CPEB2 A/B ratio, mediated through an increase
in CPEB2B, is directly correlated to anoikis resistance, and 2) CPEB2A and B regulate
the expression of multiple key regulatory genes involved in both the EMT (epithelialmesenchymal transition) and Hypoxia pathway. Furthermore, this work revealed that the
A and B isoforms of CPEB2 differentially regulate their mRNA targets, which, includes
HIF1α. Similarly, almost a decade ago, Chen (63) and colleagues theorized that CPEB2’s
interaction with translational factor, eukaryotic elongation factor 2 (eEF2) disrupted the
rate of a protein’s translational elongation (82), including that of mRNA target, HIF1α (63).
Chen used tethered function and co-IP assays that suggested the direct binding between
both CPEB2-eEF2 and CPEB2- HIF1α mRNA is required to disrupt HIF1α polypeptide
elongation and suppress translation (63). Although this work recognizes that there are
indeed at least two CPEB2 splice variants, CPEB2A and CPEB2B, it did not analyze the
change in expression of the CPEB2A and B ratio during chronic hypoxia, nor how that
could change the outcome of HIF1α translation. Previously we have used next generation
sequencing and Click-It nascent protein assays to report that CPEB2A and CPEB2B
regulate the translation of HIF1α in opposing manners. This finding could suggest that
chronic hypoxia exposure is required to produce enough of the CPEB2B isoform to
override the A isoform, and successfully induce HIF1α translation. If this is indeed the
case, we hypothesize that CPEB2-regulated translation is working either alongside or
independently of HIF1α stabilization to maintain HIF1α levels during chronic hypoxia.
Material and Methods
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Cell culture
HUVECs (CRL-1730), PAECs, (PCS-100-022), and HEK293t’s (CRL-1573)) were
all purchased from ATCC (American Type Culture Collection) and cultured according to
manufactures instructions (133). HUVEs and PAECs were both grown in EBM-2 media
supplemented with the EGM-2 bullet kit (purchased from Lonza). No additional serum
was used for cell culture (133). HEK393 cells were grown in complete DMEM (purchased
from ThermoFisher) supplemented with 10% FBS, 5% Penn/Strep. All experiments were
performed on HUVEC’s and PAECs ranging from passage 1 to passage 6. When needed,
cells were split with Trypsin-EDTA (0.25%) (133). When harvesting, cells were rinsed in
1x PBS followed by dish/plate detachment using Nunc cell scrapers (ThermoFisher).
Samples were then centrifuged at 3.5 RPM x 5 min at 4 ºC. The supernatant from each
sample was discarded, and cell pellets were either lysed and prepared for downstream
applications or immediately placed in -80ºC for future use.

Antibodies and reagents
Three different HIF1α (105SS and 610958) antibodies were used from Novus
Biotechnologies and BD Transduction Laboratories.. Cycloheximide (C7698) was
purchased from Sigma-Aldrich. Bortezomib was purchased from Sigma. Click-it protein
reaction buffer kit was purchased from ThermoFisher. Biotin was purchased from Sigma.
All primers and RNA sequences used in this study were purchased from Integrated DNA
Technologies (IDT).

Hypoxia exposure

20

A Modular Incubator Chamber (MIC-1) was purchased from Billups-Rothenberg
Inc. A tank of custom hypoxia mix was purchased from Airgas USA LLC (2% oxygen, 5%
carbon dioxide, plus balance nitrogen, size 200 certified standard-spec cga 580) (133).
Cells plated on 10cm dishes, 6-well plates, or 24-well plates (Corning, Sigma Aldrich)
were placed in the chamber with humidified air. Hypoxic air was flushed into the tank for
3-5 minutes, sealed, and added to a 37 °C incubator for 10-15 minutes before readministering hypoxic air for another 3-5 minutes (133). Cells were left in the chamber
and incubated at 37˚C for indicated times.

Antisense oligonucleotide and plasmid transfection
ASOs and plasmids were both transfected using Lipofectamine 2000 reagent
(11668019) purchased from ThermoFisher. Each transfection master mix was incubated
in Opti-MEM for 20 minutes prior to adding to serum-starved cells. Cells were then
incubated for 12-24 hours (12hr for plasmid / 24 hours for ASO transfection) before
replacing media with complete medium (133).

Quantitative “Splicing” RT-PCR
cDNA was synthesized using the Superscript III kit according to the manufacturers’
instructions (Life Technologies). cDNA libraries were subjected to traditional PCR as
described previously (54,55). using primers located on either side of exon 3 of the CPEB2
gene

as

described

previously

(54,55)

Ratios

were

then

densitometry/ImageJ, as described by us previously (54,55, 133).
Immunoblotting
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calculated

using

Total protein (20–30 μg) was separated on 10% polyacrylamide gels. Samples
were transferred to PVDF membranes and probed with the appropriate antibody as
described previously (54,55,133).

Streptavidin-biotin affinity pull-down assay
Protocol was adapted from Chen et al., 2012 (63). Biotinylated RNA HIF1α 3’ UTR
sequences surrounding the CPE site were purchased from IDT. Cells transfected with
5µg/plate of either CPEB2A-flag tagged or CPEB2B-flag tagged were harvested and
lysed via freeze-thaw in binding buffer. FLAG-tagged CPEB2 isoforms were
immunoprecipitated as described previously (54, 109) then incubated with biotinylated
RNA sequences in binding buffer (100mM KCL, 10mM HEPES, 0.1 mM CaCl2, 1 mM
MgCl2, 5% glycerol, 100 µM ZnCl2, 0.1 mg/mL BSA, and 1x protease phosphate cocktail
and 1x RNAse out, plus 5mM DTT and tRNA) (133). Samples were incubated at room
temperature for 30 minutes followed by overnight rotation at 4ºC with streptavidin beads
pre-washed in binding buffer. Beads were then washed in 1x binding buffer three times
and proteins were eluted Laemmli buffer.

Electrophoretic mobility shift assay
Biotinylated mRNA sequences were incubated with immunoprecipitated CPEB2AFLAG protein in binding buffer (54,63) then electrophoresed on a 5% acrylamide gel in
0.5 x TBE. Fluorescent bands were visualized.

siRNA Transfection
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Custom and previously validated siRNA against CPEB2B (54,55) was transfected
into HUVEC’s at a concentration of 10-15 µm using Lipofectamine 2000 according to
manufacturer’s instructions (ThermoFisher). PAECs were transfected with siRNA at
10µM using Lipofectamine 3000 according to the manufacturer’s instructions
(ThermoFisher) (133).

Nascent protein labeling
Protocol was adapted from DeLigio et al, 2017 (54) Cells were incubated in
methionine-free medium with 1000x L-azidohomoalanine (AHA) for four hours, as
described by the manufacturer (ThermoFisher). Cells were then harvested as previously
described and lysed in lysis buffer (1% NP-40 in 50 mM Tris-HCl, pH 8.0, 1 x protease
and phosphatase inhibitors, added fresh) (133). Cells were then sonicated and
centrifuged to clear the lysate. Nascent proteins were labeled with biotin using the Clickit protein reaction buffer kit (ThermoFisher) according to the manufacturer’s instructions.
Nascent proteins were precipitated using streptavidin-coated magnetic beads. Following
4 washes in PBS 7.4 pH +/- 1% NP40, samples were subjected to PAGE-immunoblot
(133).
Cyclohexamide treatment
In mammalian cell culture, 2-10 µg/mL of cycloheximide is commonly used, and is
incubated in the cell culture for 4-6 hours before harvesting (110-112). Thus, we exposed
HUVECS and PAECs to the indicated amount of hypoxia prior to incubation in 5-10ug/mL
of cyclohexamide per 10 cm dish 4 hours before cell harvest.
Bortezomib treatment.
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Bortezomib was added to HUVECs as previously described (113,114). In brief,
HUVECS were incubated in 1000x bortezomib for six hours followed by exposure to
hypoxia as described above. Cells were then harvested and probed for HIF1α expression
via western blot analysis.
Table 1. Oligonucleotide sequences. This table represents the sequences purchased
from IDT to be used in our in vitro analyses. Antisense oligo’s represent the knockdown
sequence for CPEB2B and the sense sequence to be used as a control in our vascular
cell experiments. The competitive splice PCR was used to quantity CPEB2B A/B RNA
levels. Biotinylated 3’UTR was used for streptavidin-biotin affinity pull down assays.

Name of primer

5’ 3’ sequence

CPEB2B antisense oligo (ASO-B) mGmGmCmUUGUAGGUCUUAUCmUmGm
GmUmC

Control-antisense oligo (c-ASO)

mCmGmGmAACATCCAGAATAGmAmCmC
mAmG

Competitive splice CPEB2B A/S
PCR

Biotinylated 3’UTR HIF1a

F: GCAGCAGAGGAACTCCTATAAC
R: CAAAGAGTGGCATATTCAAACTGCA
CUAACACUAACTCTAUUGUUUUGUUACA
UCAAUAAACAUCUUGUGGACCA

Results
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CPEB2 splice variants differentially bind to and regulate HIF1α protein
expression during chronic hypoxia
To determine a link between HIF1α and CPEB2 during hypoxia, we exposed
immortalized human umbilical vascular endothelial cells (HUVECs) and human
pulmonary arterial cells (PAECs) to different amounts of hypoxia (Figure 3A, B). As was
expected, HIF1α expression dramatically increased at 4 hours of hypoxia, and remained
elevated well into 96 h of hypoxia (Figure 4B, D). Based on previous literature, we have
defined the 4 h time point as “acute hypoxia” and the 96 h time point as “chronic hypoxia”
in vitro (80,81). On the other hand, CPEB2 A and B ratio, detected by mRNA levels in
lieu of a CPEB2 A vs B specific antibody to detect protein, did not appear to change
drastically until the 72-96 h (Figure 4A, E), or chronic hypoxia, time point. More
importantly, at this later time point the CPEB2A/B ratio became strongly negatively
correlated to HIF1α expression (Figure 4E). Therefore, we hypothesized that, as the
hypoxic stress response progresses, there is a shift in the regulatory machinery for HIF1α
protein expression to maintain HIF1α protein during extended exposure.
A vast amount of literature confirms that CPEB proteins bind to their target mRNA
sequences via a CPE consensus sequence in the 3’UTR (Figure 5A, B) (42,61,62).
Moreover, some CPEB proteins, such as CPEB1, bind to their target in order to repress
translation. Based on previous studies performed in our lab, however, we have concluded
that only one CPEB2 splice variant represses translation, while the other enhances it.
This finding convinced us to investigate the binding of CPEB2A and CPEB2B to its bestknown target, HIF1α, to determine if differential binding is what leads to opposing
regulatory roles of the two isoforms. To detect direct binding, we performed a streptavidin-
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biotin affinity pulldown (SBAP) assay using biotinylated HIF1α 3’UTR incubated with Flagtagged CPEB2A or CPEB2B. Initially, what we discovered was that CPEB2A binds to the
3’UTR of HIF1α with stronger affinity than it binds to CPEB2B (Figure 5C).
As a result, we analyzed the mRNA sequence of HIF1α further, and detected
another CPE consensus sequence in exon 10 for which we consequently designed a
biotinylated oligonucleotide. The results, as shown in Figure 5D, revealed that CPEB2B
binds with stronger affinity to the biotinylated exon 10 of HIF1α. These results indicate
that differential binding may alter the regulation of target mRNA.

CPEB2B-dependent translation helps to maintain HIF1α during chronic hypoxia
In order to determine if HIF1α is dependent on CPEB2 A/S during hypoxia, specific
antisense oligonucleotides and siRNA against CPEB2B designed to block the SRSF3sequence specific binding site on the CPEB2 transcript were synthesized as a way of
knocking down CPEB2B in vitro (Figure 6A). Our analysis revealed that CPEB2B-targeted
knockdown, either through ASO-B or siCPEB2B, led to minimal change in HIF1α protein
expression during acute hypoxia, but significantly depleted HIF1α during chronic hypoxia
in HUVEC’s (Figure 6B, C). Using our competitive splice RT-PCR analysis, we confirmed
that CPEB2B was indeed being knocked down both during acute hypoxia and chronic
hypoxia when compared to control conditions (c-ASO) (Figure 6D, E). Thus, CPEB2Bdependent regulation of HIF1α protein is presumably occurs only during chronic hypoxia.
This finding is consistent with our previous conclusion that there is a shift in HIF1α
regulation as hypoxia persists.
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To detect whether translational inhibition impacted HIF1α during hypoxia, we
exposed HUVECS and PAEC’s to acute (4 h) and chronic (96 h) hypoxia, while adding
cycloheximide, a translational inhibitor, prior to cell harvest (Figure 7A, B). Interestingly,
our results exhibited minimal impact on HIF1α expression when translation was inhibited
during acute (4 h) hypoxia, while inhibiting translation during chronic (96 h) hypoxia
significantly impeded HIF1α expression (Figure 7C).
Indeed, HIF1α protein stabilization may still be occurring during chronic hypoxia
exposure, but we suggest that it may be alongside translational regulation of HIF1α to
maintain HIF1α levels as hypoxia endures. Therefore, to examine the extent to which
HIF1α protein expression is controlled by protease activity during acute (4 h) and chronic
(96 h) hypoxia, a proteasomal inhibitor was used. Bortezombib, or VelcadeTM, is a
chemotherapeutic agent that can be used to inhibit protease activity. Therefore, we
incubated cells in Bortezomib during hypoxia exposure to determine how protease activity
impacts HIF1α during both acute (4 h) and chronic (96 h) hypoxic exposure (Figure 8).
Our results were inconclusive, reflecting the possibility that protease activity might already
be exhausted during hypoxic exposure, and an accurate measurement of HIF1α
expression, and how Bortezomib impacts it, might not have been possible.
As already mentioned, we have used Click-it chemistry alongside ectopically
expressed CPEB2 splice variants to reveal that CPEB2A and CPEB2B regulate the
translation of HIF1α in opposing fashions. In short, to analyze nascent protein through
Click-it based chemistry, a methionine mimic known as L- azidohomoalanine (AHA)
containing a small azide tag can be introduced into cells in culture where it covalently
binds to the endogenous methionine tRNA in actively synthesizing proteins (83). In other
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words, AHA and its azide moiety will incorporate itself into newly translated proteins.
Azides are a class of chemical compounds that have a strong affinity for alkyne
compounds such as biotin. Therefore, the nascent proteins tagged with azide can be
pulled down with biotin and probed accordingly. Our past results confirmed that, when
CPEB2A is inhibited, HIF1α translation is enhanced, whereas with CPEB2B knockdown,
we see the exact opposite. This indicates whether CPEB2B acts to increase HIF1α
translation when it is expressed. In this study we therefore analyzed HIF1α expression
during acute and chronic hypoxia and +/- CPEB2B to confirm that CPEB2 A/S was
regulating HIF1α expression during hypoxia in a translational manner. Indeed, our results
confirmed that when CPEB2B was knocked down via ASO-B, translation of HIF1α was
inhibited, but more importantly, this inhibition was specific to chronic (96 h) hypoxia. As
Figure 9A suggests, there was no indication of translational control of HIF1α during acute
(4 h) hypoxia. Moreover, nascent protein labeling was repeated in a primary cell line
(PAEC’s) and similar results were observed (Figure 9B).
Our study indicated that, in addition to being dependent on CPEB2B, eIF3h, a
binding partner of CPEB2, is also required for the translation of HIF1α. The eukaryotic
initiation factor, eIF3h, is part a subunit of the eiF3 translational initiation protein, and
based on our results, may be part of the pre-initiation complex that aids CPEB2B in
inducing HIF1α translation via preferential association with HIF1α (Figure 10A, B).

Discussion
On a molecular level, chronic hypoxia poses a threat to the cellular hypoxic stress
response. Persistent or recurring oxygen deprivation can cause unrelenting HIF1α
expression, which can lead to irreversible and ultimately detrimental vasculature changes.
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In addition to hypoxic diseases, HIF1α is commonly found to play a role in tumor
progression, suggesting that the discovery of new therapeutics that target HIF1α may be
beneficial in the treatment of cancers (93-95). It is well-established that many types of
solid tumors possess a hypoxic core that activates survival pathways, such as that of
HIF1α. Considering the lack of efficacy of a number of chemotherapies, there has been
growing interest in the development of both direct and indirect HIF1 inhibitors capable of
cutting off life support for these tumors (93-95). Indeed, HIF1α knockout studies have
been performed and confirmed that complete HIF1α-/- embryos show lethality due to the
crucial role of HIF1α in proper development. Therefore, partial, or tissue-specific
knockdowns would need to be considered. Interestingly, a study performed in 2011 in
mice revealed that knocking down HIF1α specifically in the pulmonary smooth muscle
cell led to depletion of vasculature cell proliferation following chronic hypoxia, concluding
that HIF-1α in pulmonary vascular smooth muscle contributes significantly to the
remodeling events induced by chronic hypoxia in pulmonary vessels (19). This paper
helped give us rationale for our study, in which we have aimed to characterize a potential
regulator of HIF1α during chronic hypoxia.
We began this study after our discovery that the alternative splicing of CPEB2
plays a role in not only anoikis resistance of triple negative breast cancer, but also in more
regulatory processes, like that of the hypoxic pathway (54). More specifically, we had
shown that the A and B isoforms of CPEB2 were regulating the translation of HIF1α in
opposing fashions: the CPEB2A isoform inhibited translation, whereas CPEB2B
enhanced it. At this point, however, it was still unclear what role, if any, CPEB2 A/S was
playing within vasculature cells during the hypoxic stress response. Therefore, we began
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this study by performing a hypoxic time course that would give us insight into how the
expression of the CPEB2 A/S and HIF1α correlated during hypoxic exposure. We found
was that by 4 hours of hypoxic exposure, potent HIF1α protein levels can be detect, but
the CPEB2A/B ratio does not change considerably until approximately 72 h of hypoxia.
However, at this time point (72 h) the decrease in the CPEB2A/B ratio as a result of an
increase in CPEB2B became strongly negatively correlated with HIF1α expression.
In order to strengthen this finding, one would need to develop a CPEB2B specific
antibody to detect CPEB2B protein, rather than rely on the RNA levels (via RT-PCR and
competitive PCR analysis). Nonetheless, this finding made it apparent that the B isoform
of CPEB2 was a splice variant that responds to chronic stress, like that of hypoxia. This
conclusion is not far off-base, if one were to consider that the only other time CPEB2B
has revealed itself thus far is during the progression of anoikis resistance – another type
of longstanding stress (96-98).
As already cited in this paper, we know that CPEB proteins bind to their target
mRNA sequences via a CPE site in the 3’UTR (42). For this reason, the next question we
wanted to answer in this study was whether CPEB2A and CPEB2B differentially regulate
HIF1α due to differential binding. Interestingly, HIF1α 3’UTR preferred to bind to CPEB2A,
while a secondary CPE consensus sequence in exon 10 of HIF1α preferred to bind to
CPEB2B. To date, there are few findings that can confirm CPEB elements bind to CPE
consensus sequences outside of the 3’UTR. An alternative possibility could be that
CPEB2B is binding to RNA secondary structures with more preference than to the CPE
consensus site of its mRNA targets. This could be explained the fact that the lesser known
CPEB family members, CPEB3 and CPEB4, have previously been shown to be
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functionally different from the original CPEB1, and both interact with uridines that are
single-stranded as well as with double-stranded stems (74). We hypothesize that
CPEB2B could be doing the same. Over the years it has become apparent that CPEB
family members are distinctively different from one another, so one should not rule out
the possibility that individual splice variants are as well. What we do know is that CPEB
family members contain a zinc finger domain that is necessary for stable RNA binding,
including secondary structure RNA binding, but these zing fingers do not confer
specificity. Therefore, one could consider the possibility that there is an element (e.g.,
phosphorylation site) within exon 3 of CPEB2 that conveys a message to it’s zinc finger
domain to bind to the mRNA’s secondary structure and regulate its translation. Perhaps
another possibility could be a change in CPEB2’s structure when exon 3 is present, thus
altering its binding site/preference. One would need to perform an RNA foot-printing
analysis, to confirm that CPEB2B does indeed exhibit differential binding to HIF1α. In
brief, CPEB2A and CPEB2B would be comparatively incubated with fluoro-labeled HIF1α
RNA, followed by incubation with RNAses that specifically cut RNA secondary structures
(e.g., single stranded RNA or RNA stem loops). One could then compare the fluorescently
labeled RNA footprint of digested HIF1α to those protected by CPEB2A or CPEB2B
binding (74). Furthermore, this analysis could provide useful information on the properties
of CPEB mRNA targets.
In addition to determining how CPEB2A and B differ in their binding to HIF1α, we
also wanted to confirm that CPEB2A/S can be targeted to regulate HIF1α. Therefore, we
designed ASOs that knocked down CPEB2B in both HUVEC and PAEC cell lines. What
we discovered is that inhibition of CPEB2B impacted HIF1α protein levels only during
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chronic hypoxia. The significance of this finding was two-fold. First, it indicates that
CPEB2B may be a potential target in the inhibition of HIF1α activity during chronic hypoxic
disorders. Second, it strengthens the rationale for our hypothesis that there is more to
HIF1α expression during chronic hypoxia than HIF1α protein stabilization. Perhaps there
is a shift in how HIF1α levels are maintained as we progress into chronic (72-96 h)
hypoxia, which would dually explain the strong negative correlation between CPEB2A/B
ratio and HIF1α protein in our time course. Another possibility is that chronic stress led to
the induction of CPEB2B, which, in turn, increased nascent HIF1α production and led to
an increase in its stabilization.
To determine the extent to which protein synthesis impacts HIF1α expression
during chronic hypoxia, compared to protein stabilization, we inhibited translation during
acute and chronic hypoxic exposure. Our findings suggested that there is significant
translational control over HIF1α once the cells progress into chronic hypoxia.

A

substantial amount of literature supports the notion that oxygen deprivation leads to the
suppression of canonical translation of proteins (15-17). During acute hypoxic exposure
in our study, we witnessed minimal depletion of HIF1α levels when exposed to the
translational inhibitor, cycloheximide. This was expected, since it agrees with the dogma
that oxygen deprivation stops HIF1α from being hydroxylated, in turn stabilizing the
already generated HIF1α protein. Thus, inhibiting nascent protein production would not
impair what was already present. On the other hand, by the time the cells have reached
chronic hypoxic exposure, one could theorize that new HIF1α protein will need to be
produced to maintain a persistent level of HIF1 activity. This could explain why
translational inhibition had a stronger imposition on chronic hypoxia than acute.

32

Moreover, we were able to conclude whether this translational control was indeed
dependent on CPEB2B, once again strengthening the potential of CPEB2B as a
therapeutic target for HIF1α inhibitors. In addition to CPEB2B, we also discovered that a
binding partner of CPEB2B, eIF3h, is equally important for the translation of HIF1α.
Recent evidence in zebrafish reveal an essential role for this non-core subunit of eIF3 in
proper polysome loading of mRNA targets, although its specific interactions are still poorly
defined (99,100). Other studies have detected eIF3h in stress granules, which, CPEB2
has also been found to reside in (101,102). Based on our previous published work that
confirms CPEB2 and eif3H are binding partners, and our findings that HIF1α is dependent
on the presence of both translational regulators, one might hypothesize that CPEB2B and
eIF3h are part of a complex that forms within stress granules following the exposure to
stress as a means to aid in the translation of dormant, untranslated, essential proteins,
like HIF1α, for the hypoxic stress response (52).

Figure 3. CPEB2B expression increases during chronic hypoxia. (A) HUVECS and (B)
PAEC’s were subjected to a hypoxia chamber (2% O2) for the indicated amounts of time.
HIF1α and B-actin antibodies were used when specified to quantify protein expression
after immunoblotting (top blots). Quantitative-splicing RT-PCR was performed to quantify
CPEB2 A/B RNA levels (bottom gels). Both the CPEB2A and B variants are indicated
with an arrow.
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Figure 4. CPEB2A/B ratio is negatively correlated to HIF1α protein expression during
chronic hypoxia. Results for both cell-types from Figure 3 were evaluated measured via
ImageJ. The average CPEB2 RNA A/B ratio was calculated and graphed accordingly for
(C) HUVECS and (F) PAECs. For (A) and (C), the Y-axis represents CPEB2 A/B ratio
and X-axis represents time in Hx. HIF1α total protein expression was quantified using
densitometry and graphed for XY linear regression for (D) HUVECS and (G) PAECs. For
(B) and (D), the Y-axis shows HIF1α total protein and the X-axis represents time in Hx.
(E) The A/B ratio against HIF1α levels were then correlated. The Peason’s R and pvalues for each graph are indicated.* indicate a p<0.05 for repeated ANOVA measures.
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Figure 5. CPEB2A and CPEB2B differentially bind the 3’UTR region and a region of
HIF1α exon 10. (A) Schematic representation of the consensus sequence site in the
3’UTR of HIF1α, located within base pair 270-276. (CPE: cytoplasmic polyadenylation
element, pA: alternative polyadenylation site). (B) Flag-tagged CPEB2A expressing cells
were harvested and incubated with FITC-conjugated 3’UTR HIF1α mRNA prior to EMSA.
IgG = immunoglobin G. (C) Biotin-streptavidin affinity (SBAP) was performed on
immunopurified flag-tagged CPEB2A and CPEB2B samples incubated with sequences
corresponding to the 3’UTR of HIF1α. (D) Flag-tagged CPEB2A or CPEB2B expressing
cells were harvested and incubated with biotinylated 3’UTR HIF1α mRNA or biotinylated
exon 10 HIF1α mRNA. Samples were consequently pulled down via streptavidin-biotin
affinity, and blotted for Flag.
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Figure 6. Targeting CPEB2B can be used to inhibit HIF1α expression exclusively during
chronic hypoxia. (A) Schematic representation of ASO-targeted against CPEB2B. (B)
HUVECs were pretreated with either mock, control siRNA or siRNA targeted against
CPEB2B prior to hypoxia exposure (2% O2) for the indicated times. Protein was subjected
to either western blot with the specified antibodies (top gels) or to splicing RT-PCR for
CPEB2 A vs B (bottom gels). (C) HUVECs were pretreated with either control ASO or
ASO against CPEB2B and prior to hypoxia exposure and subjected to the same western
blot and RT-PCR analysis as in (B). Blots were densitometrically analyzed by Image J
and graphed accordingly. (D-G) Changes in either CPEB2 A/B ratio (D, F) or HIF1α
protein expression (E, G) were assessed using Image J densitometry and graphed
accordingly. Error bars indicate SD. Asterisks represent significance between 96h control
and 96h siCPEB2B or ASO-B * P>0.01.
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C

Figure 7. HIF1α levels are maintained by translation during chronic hypoxia (A) PAECs
(cell passage 5) and (B) HUVECs (cell passage 3-6) were grown to 75% confluency in
10cm plates. Cells were then exposed to hypoxia (2% O2) for the specified time points.
4h prior to harvest, cells were incubated with 5 µg/mL cycloheximide, a translational
inhibitor, (+) or complete media for the control (-). HIF1α and B-actin antibodies were
used to detect total HIF1α protein via SDS PAGE western blot analysis. (C) ImageJ
software was used to densitometrically quantify HIF1α levels +/- cycloheximide and
graphed accordingly for both cell types. Error bars indicate mean with SD. Asterisks
represents statistical significance between 1) 0 h and 4 h control and 2) 4 h cyclo and 96
h cyclo, * P <0.005.
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A

Figure 8. The impact of proteasomal inhibition on HIF1α expression during hypoxia. (A)
HUVEC’s (cell passage = 4) were trypsinized and plated on 10cm dishes and grown to
75% confluency. Once grown, cells were incubated in 1000x bortezomib, a protease
inhibitor, (+) or control media (-) for 6 h prior to hypoxia exposure (2% O2) for the specified
time points. HIF1α and B-actin antibodies were used to detect HIF1α protein via Western
blot analysis.
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A

N=1

N=2

B

Figure 9. HIF1α protein is synthesized during chronic hypoxia in a CPEB2B-dependent
manner. (A) HUVECs were grown to 75% confluency prior to transfection with ctrl-ASO
or ASO-B prior to hypoxia exposure (2% O2) for the indicated time points. 4-6 hours prior
to harvest, HUVECS and (B) PAECs were incubated in 1000x L-AHA for nascent protein
labeling. Following harvest, newly synthesized proteins were pulled down via streptavidinbiotin affinity assay. Labelled proteins were immunoblotted for HIF1α and B-actin. Two
HUVEC biological replicates (N=1, N=2) are shown for (A). *=p<0.05 via repeated
measures with ANOVA.
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A

B

Figure 10. HIF1α translation is dependent on potential CPEB2-binding partner, eIF3h.
(A) HEK293ts were grown to 75% confluency and transfected with the indicated siRNA
(ctrl/eIF3H) and rescued with the indicated plasmids (vector/CPEB2B).

Cells were

harvested and immunoblotted with the specified antibodies. (B) A subset of HEK293t
were additionally incubated in L-AHA prior to harvest and subjected to nascent protein
labeling and streptavidin-biotin affinity assay, and immunoblotted using the antibodies
specified.
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CHAPTER THREE
THE ROLE OF CPEB2B ALTERNATIVE SPLICING IN REGULATING VASCULATURE
REMODELING

Abstract
To confirm whether the regulation of HIF1α through CPEB2 is clinically relevant to
chronic hypoxic disorders, we characterized how targeting CPEB2 A/S impacted
downstream cellular responses to hypoxia, and in turn, vascular remodeling. Since
angiogenesis is at the forefront of managing remodeling in the pulmonary system, its
direct targeting could delay the onset of pulmonary arterial hypertension and other
hypoxic diseases exhibiting dysregulated vasculature changes. Therefore, we
hypothesized that, through their regulation of HIF1 and its direct targets (i.e.: VEGF),
CPEB2 splice variants can be targeted to alleviate angiogenesis and vascular remodeling
resulting from chronic hypoxia. In this chapter, we aimed to characterize the role that
CPEB2 A/S plays in regulating the HIF1-induced gene and pro-angiogenic factor, VEGF.
In addition to our in vitro protein analyses and in lieu of an in vivo model, we implemented
our 2D cell culture techniques into 3D in order to better mimic angiogenesis in vivo. If our
hypothesis stands, targeting CPEB2 would be a promising target for indirectly inhibiting
pathogenic angiogenesis and vascular remodeling that leads to Pulmonary Arterial
Hypertension (PAH).
Introduction
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PAH refers to a group of diseases characterized by elevated pulmonary pressure
caused by irreversible, hypoxia-induced changes to lung vasculature. PAH affects 378
per 100,000 Americans, resulting in 200,000 hospital visits and nearly 1000 new US
cases per year (18). Moreover, without intervention, the sustained pressure load in
patents with PAH can hypertrophy the right ventricle of the heart and cause right-sided
heart failure (21,22). As a result of few significant therapeutic advancements against
chronic hypoxia-induced PAH in recent years, there has been little change to the
morbidity and mortality of this class of disease. Therefore, the discovery of new targets
for alleviating the pathogenic cellular changes associated with hypoxic disorders is vital
to the prognosis of PAH.
PAH is considered to be a dysregulated pro-angiogenic disease found in patients
suffering from COPD, sleep apnea, and asthma (131). Recently, VEGF has come to light
as a pivotal angiogenic protein dysregulated in PAH (Figure 11), but to date, its potential
as a target for alleviating chronic hypoxia-induced pathologies that can lead to PAH has
been paradoxical. (129-132). A rat model that inhibited the activity of VEGF generated by
Tuder and colleagues in 2005 showed that inhibition of VEGF led to severe PAH both
under normoxic and hypoxic conditions (132). In this 2005 study, it was reasoned that
VEGF is also responsible for pulmonary endothelial cell maintenance and survival, but
interestingly, its total ablation induces apoptotic-resistant endothelial cells that would
promote vascular occlusion and remodeling, and thus PAH (132). Although other studies
have proposed that inhibition of VEGF ameliorates vascular remodeling, this paradox
indicates that there is still a significant amount to learn about how VEGF is dysregulated
during PAH and chronic hypoxia, and what specific cellular responses VEGF is
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responsible for (129-132). For instance, a 2020 publication in the Journal of Clinical
Investigations proposed that HIF1 and its direct targets, including VEGF mRNA, are
upregulated in the pulmonary cells of patients with PAH (132). This finding suggests a
role of these proteins in the promotion of pulmonary pathogenesis and PAH.
Therefore, in this chapter we aim to characterize how the indirect inhibition of
VEGF via targeting CPEB2 splice variants can be used to regulate VEGF, and thus
alleviate its angiogenic activity. Moreover, in order to analyze angiogenesis in vitro, we
have developed a 3D vascular cell assay that can be induced by hypoxia to activate
angiogenesis-like sprouting. 3D cell culture can serve as bridge between in vitro and in
vivo analysis, by providing the investigator the opportunity to analyze protein-protein
interactions and cell-cell interactions that are harder to detect in 2D cell culture. Sprouting
assays, or capillary assays, are one such example of an analysis that offers an insight
into a cell’s interactions with the environment during hypoxia. Following hypoxic exposure,
the mitogen activity of VEGF leads to new capillary formation on the existing pulmonary
vasculature. Thus, we hypothesized that a sprouting assay would help us determine if
CPEB2B targeting can be used to inhibit the HIF1α -dependent cellular response of
angiogenesis. If so, targeting CPEB2 could be a promising target for indirectly inhibiting
angiogenesis and pathogenic vascular remodeling that leads to PAH.

Material and Methods
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Cell culture
HUVECs (CRL-1730) were purchased from ATCC (American Type Culture
Collection) and cultured according to manufactures instructions (133). HUVECs were
grown in EBM-2 media supplemented with the EGM-2 bullet kit (purchased from Lonza)
(133). All experiments were performed on cells passage 1 to passage 4 plated in 10cm
dishes. When needed, cells were split with Trypsin-EDTA (0.25%). When harvesting,
cells were rinsed in 1x PBS followed by dish detachment using Nunc cell scrapers
(ThermoFisher). Samples were then centrifuged at 3.5 RPM x 5 min at 4 ºC (133). The
supernatant from each sample was discarded, and cell pellets were either lysed and
prepared for downstream applications or immediately placed in -80ºC for future use.

Antisense oligonucleotide and plasmid transfection
ASO-B and plasmids were both transfected using Lipofectamine 2000 reagent
purchased from ThermoFisher (133). Each transfection master mix was incubated in
Opti-MEM for 15-20 minutes according to manufacturer’s instructions prior to adding to
cells pre-starved (20 minutes) of complete media for 20 minutes. Cells were then
incubated for 12-24 hours (12hr for plasmid / 24 hours for ASO transfection) before
replacing media with complete medium (133). The HA-HIF1alpha-pcDNA3 plasmid was
a kind gift from Dr. William Kaelin (Addgene plasmid #18949) (133).

Immunoblotting
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Total protein from cell lysates (15–30 μg) was separated on 10% SDS
polyacrylamide gels. Samples were transferred to PVDF membranes and probed with the
appropriate antibody as described previously (54,55, 133).

Anti-VEGF (MA513182)

primary antibody was purchased from ThermoFisher.

HUVEC spheroid generation
HUVEC spheroids of defined cell number were generated as previously described
(115-117). In brief, HUVECS below passage 7 were grown to 75-90% confluency and
trypsinized. Cells were re-suspended in EGM-2 Lonza medium containing 20%
methylcellulose and cultured as hanging drops (500 cells/25 µL) onto the lids of 100 cm2
petri dishes (~100 droplets/dish) and incubated at 37 °C overnight to form spheroids
(133).

In vitro sprouting assay
Approximately 100 HUVEC spheroids were collected by gently washing with 10x
PBS and centrifuging at 500 x g for 5 min. On ice, rat-tail collagen was mixed with DMEM
(8:1) and NaOH (enough to change solution from yellow to faint pink). Spheroids were
resuspended in EGM-2 Lonza media supplemented with 30% FBS, and 0.25%
methylcellulose. Immediately following the addition of the collagen:DMEM mixture to the
spheroids, 500uL of each spheroid mixture was rapidly plated into a 24-well plate and
allowed to polymerize at 37C for 30 minutes. After polymerization, cells were exposed to
hypoxia as described above. Sprout number per spheroid was counted, as well as
cumulative sprout length using the measurement tool in FIJI/ImageJ (117).
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Results
Targeting CPEB2B can be used to inhibit VEGF during Chronic Hypoxia
As a master promoter of vasculature growth, VEGF protein expression can be a
reliable indicator of angiogenic onset during hypoxic exposure (Figure 10). Here we
tested the hypothesis that targeting CPEB2 could be used to regulate downstream cellular
responses dependent on HIF1α, including that of VEGF. Consequently, we used western
blot analysis to quantify VEGF expression in endothelial cells exposed to one of two
conditions: 1) HUVECS transfected with ASO-B and rescued with ectopic HIF1α and
exposed to chronic hypoxia, or 2) HUVECs and PAEC’s exposed to acute and chronic
hypoxia and incubated with cycloheximide. These analyses allowed us not only to test
our hypothesis, but also confirm that VEGF is dependent on HIF1α expression during
hypoxia. As evident in Figure 12A, targeting CPEB2B through our ASO-B was moderately
effective in downregulating VEGF during chronic hypoxia, likely through HIF1α inhibition
(Figure 12B). Interestingly, some literature suggests that HIF2 may also have regulatory
control over VEGF which could indicate the variation among our results (91,92). To test
this possibility, HIF2 expression could be quantified using HIF2a antibodies. However,
even with the potential that HIF2 is aiding in the regulation of VEGF during hypoxia, it did
not completely return VEGF expression to its full potential during chronic hypoxia,
indicating the necessity of HIF1α for VEGF induction during hypoxia.

CPEB2 splice variants play a role in regulating angiogenesis induced by chronic
hypoxia
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In addition to protein analysis, we examined how CPEB2B-directed HIF1α
inhibition impacts angiogenesis through 3D cell culture sprouting assays. Our results
suggest that, when ASO-B transfected vasculature spheroids are exposed to 48+ h of
hypoxia, there is a significant decrease in both the length and number of sprouts,
compared to the control ASO transfected spheroids (Figure 13A). Interestingly, we also
observed wider sprouts in the ASO-B transfected spheroids (Figure 13B). From these
findings, we conclude that possibly the additional surface area resulting from fewer
sprouts permits the sprouts to expand more than those typical of a vasculature network.

Discussion
To confirm that the regulation of HIF1α by CPEB2 A/S was clinically applicable to
hypoxic disorders, we wanted to determine how targeting CPEB2B effected
angiogenesis: a hallmark sign of the hypoxic stress response. As aforementioned, the
mitogenic protein, VEGF, is most reputable for its role in activating angiogenesis through
a series of signal transduction pathways that increase cell proliferation and vascular
permeability. VEGF can therefore be a reliable protein for predicting angiogenesis in vitro.
We observed that targeting CPEB2B may be a potential mechanism for inhibiting
angiogenesis. In addition to playing a pivotal role in the hypoxic stress response, tumor
growth and metastasis both heavily rely on angiogenesis (102). More specifically,
angiogenesis through VEGF induction depends almost entirely on HIF1 expression in a
handful of cancers, including pancreatic and liver (103). Nevertheless, in our study, the
degree to which ASO-targeted CPEB2B knockdown inhibited VEGF showed some
variation from one experimental group to the next, which could imply unpredicted control
over VEGF by HIF1α depending on the type of disease. A potential reason for this could
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be in part due to the joint regulation of VEGF by HIF1 and HIF2 (104,105). There is
evidence that, as hypoxia progresses, HIF2 expression takes on a leading role in the
HSR. With that in mind, it is possible that HIF2 regulation of VEGF begins around 96 h of
hypoxic exposure and occurs alongside HIF1 regulation. This would explain why we
observed only partial downregulation of VEGF in several of the experimental groups that
were targeted by CPEB2B. Moreover, based on previous literature that suggests HIF1/2
expression differs from one cell type to the next, it might be worth examining how the
results would differ in a smooth muscle cell (103,104-105).
An alternative way to analyze how CPEB2B targeted knockdown of HIF1α effects
angiogenesis was to develop spheroids that depict the physiological interactions
occurring between neighboring cells in vitro. This analysis is achieved through a sprouting
assay, which utilizes rat-tail collagen to mimic the extra-cellular matrix that promotes new
capillary, or blood vessel, growth in vivo. In doing so, we can generate spheroids, which,
compared to single-cell culture techniques, won’t undergo apoptosis when seeded in
suspension (106). Our results suggest that, when exposed to chronic hypoxia, spheroids
that have been targeted to knockdown CPEB2B present significantly fewer and shorter
sprouts compared to the control. We suggest that this observation is indicative of impaired
angiogenesis. Interestingly, the sprouts in the ASO-B transfected cells have a wider
surface area compared to the control. We suggest that this is a result of the extra space
available when fewer capillaries form, however, there is not enough literature available to
definitively explain this phenomenon. In order to characterize this phenotype, one could
probe the sprouting spheroids with endothelial markers (e.g., CD31, CD34) to confirm
that the cell has not changed its morphology, or use an apoptosis analysis (e.g., BrdU) to
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rule out changes associated with programmed cell death (107,108). In summary, the 3D
cell sprouting assay we performed in this study gave us a preview of how CPEB2 A/S
might impact the hypoxic stress response in vivo. Taken together our results indicate that
HIF1α-dependent targets, such as pro-angiogenic factor VEGF, can be regulated via
direct targeting of CPEB2 splice variants.
Figure 11. Schematic representation of VEGF-induced angiogenesis following
transactivation by HIF1. In brief, under hypoxic conditions, HIF1α and HIF1B dimerize in

the nucleus to form the HIF1 transcription factor, that then binds to the HRE site in the
promoter of target, VEGF. Once synthesized, VEGF acts as a mitogen to signal the
induction of new blood vessel growth (i.e., angiogenesis). If chronically expressed, in
order to combat persistent hypoxia, angiogenesis can become dysregulated.
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Figure 12. Targeting CPEB2B partially inhibits VEGF expression in a HIF1α -dependent
manner. (A) HUVEC’s were transfected with c-ASO or ASO-B, or ASO-B+pHIF1α
plasmid as indicated. Media was changed and cells were subjected to normoxia or
chronic hypoxia as specified. Following cell harvest, samples were prepared and run on
an SDS-PAGE gel before HIF1α, VEGF and B-actin antibodies were used for immunoblot
analysis. (B) ImageJ software was used to analyze densitometry of each blot and quantify
total protein expression of VEGF. * indicates significance between c-ASO at 96h and
ASO-B at 96h, and ASO-B+HIF1 at 96h and ASO-B at 96h.
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Figure 13. Targeting CPEB2B is an effective mechanism for inhibiting new capillary
growth induced by hypoxic exposure. (A) HUVECs were grown to 65-70% confluency
when transfected with either c-ASO or ASO-B as indicated. After 24 h, cells were
trypsinized and spheroids were formed via the hanging drop method. Spheroids were
then subject to a sprouting assay under chronic hypoxia exposure. Images were taken on
a Leica microscope at 40x magnification. 200 µM for cASO Hx 0h, ASO-B Hx 0 h, and
ASO-B Hx 48 h. (B) cASO Hx 48 h was taken at 4x magnification, 1000µM and
subsequently zoomed in on. (C) Sprout number/spheroid was quantified (Y-axis
represents # of sprouts per spheroid and X-axis represents sample), as well as the
cumulative sprout length (Y-axis represents CSL and X-axis represents sample) using
FIJI/ImageJ. Values were graphed accordingly. N=7. * indicates significance between cASO and ASO-B at 48 h hypoxia.
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RESEARCH LIMITATIONS
Conventional 2D cell culture of human cell lines has been fundamental in the study
of humane disease as well as for evaluating anti-therapeutic efficacy. Not only does it
offer scientists highly reproducible results, 2D cell culture also promotes fast growth and
allows for ample surface adherence and uniform access to media growth factors.
However, it does not always depict the complexity of the cellular environment and its
responses as they occur in vivo. 3D cell culture methods, as we have used in this study,
provide a bridge between 2D analysis and tissue/human studies. However, to date, these
methods still fail to replicate the complex heterogenous cell composition and diffusion of
therapeutics observed in vivo (118). Thus, the use of animal models can address a
number of short comings that result from in vitro analysis. Under different circumstances,
our lab could have produced inducible transgenic mouse model that express either
CPEB2A or CPEB2B, in order to demonstrate the impact that each CPEB2 splice variant
has on the hypoxic stress response in vivo. This analysis would have strengthened our
clinical relevance and confirmed our hypothesis that CPEB2 A/S can be targeted for
therapeutic treatment of diseases that present with aberrant HIF1 activity, such as chronic
hypoxic diseases and solid tumors with hypoxic cores (102-105).
As indicated earlier, CPEB2A and CPEB2 differ by the single inclusion or exclusion
of exon 3 (54, 55). Therefore, in order to generate recombinant DNA constructs that can
be incorporated into murine stem cells for the development of a transgenic mouse, we
needed to synthesize DNA that either forced the inclusion of exon 3 via cDNA or drove
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its exclusion via the Cre/LoxP system (Table 2, 3). In addition to the CPEB2 A/B inducible
sequence, each construct contained homologous arms that surround the endogenous
DNA of CPEB2 A/B to ensure homologous recombination of the desired sequence once
transformed into murine stem cells. The murine stem cells, forming a blastocyst, would
then be injected into a pseudo-pregnant female mouse that would ultimately produce
heterozygous offspring. To produce a homozygous population, a series of crossbreeding
would commence before the induction of CPEB2A or CPEB2B. One example would be
to cross a CPEB2A +/+ mouse with a Cre-expressing mouse containing a vascular cellspecific promoter (119). A reliable pulmonary Cre-promoter for the study of lung specific
diseases is the smooth muscle cell promoter, α-SMA (119), which are the main cell-type
responsible for proliferation during chronic hypoxia. If we were to use this promoter in
our study, we could examine how driving expression of either CPEB2A or CPEB2B
impacted smooth muscle cell proliferation during chronic hypoxia, a phenotype suggested
to be controlled by HIF1 activity (120-121). Our expected results are rationalized by a
study performed in a HIF1α partial knockout murine model in 2011. The mouse models
in this study contained a homozygous conditional deletion of HIF1α combined with a
tamoxifen-inducible smooth muscle–Cre recombinase system (19). Mice were given
tamoxifen during chronic hypoxic exposure (5% oxygen) that induced the deletion of
HIF1α specifically in smooth muscle cells (19). As a result, this study determined that a
tissue specific knockdown of HIF1α during chronic hypoxia exposure diminished
pulmonary vasculature remodeling through decreased cell proliferation and motility and
alleviated pulmonary hypertension. In comparison, we would expect that our CPEB2Adriven mouse model would alleviate pulmonary hypertension through the knockdown of
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HIF1α in smooth muscle cell, while the CPEB2B-driven model that would produce
worsened pulmonary hypertension. Similarly, a study utilizing a HIF1α partial knockout
mice concluded that efficient deletion of HIF1α in mammary tumor epithelial cells led to
reduced primary tumor growth and suppressed metastasis. Perhaps, our CPEB2A-driven
mouse model would show us similar results.
Additionally, to strengthen our hypothesis that there is a shift in the control over
HIF1 maintenance as eukaryotic cells progress into chronic hypoxia exposure, we would
need to use an assay that quantified stabilized HIF1α protein levels versus nascent
protein levels. This measurement taken within a hypoxic time course could help us
pinpoint where, and if, there is a shift in the control of HIF1α. Previous literature suggests
that measuring prolyl hydroxylase activity is a reliable manner in which to quantify HIF1α
protein stabilization activity (122). This activity could be measured overtime alongside
nascent HIF1α labeling to localize the control change.
Lastly, access to and maintenance of smooth muscle cells is challenging, which
has resulted in our study relying heavily on the molecular activity of endothelial cells (i.e.,
HUVECs, PAECs).

As mentioned, smooth muscle cells are the primary cell-type

responsible for proliferation during the hypoxic stress response, leading to vascular
remodeling, a key pathophysiological sign of pulmonary hypertension (123). Moreover,
studies have shown that VEGF expression, albeit an endothelial growth factor, has been
shown to induce smooth muscle cell migration, and thus could be indirectly targeted by
CPEB2 A/S to deplete migration (124,125). Smooth muscle cells, therefore, may be a
more clinically relevant option for investigating anti-cell-proliferative pulmonary
therapeutics for diseases such as COPD and pulmonary arterial hypertension (126-128).
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Table 2: Recombinant DNA construct for CPEB2A Snapgene software was used to
generate a transgenic plasmid that could induce the expression of CPEB2B in a model.
In brief, a pKO2.2 plasmid backbone was fused to a genetic sequence synthesized from
ThermoFisher to drive the expression of CPEB2A through a Cre-Lox inducible knockout
of exon 3 of the CPEB2 gene transcript.
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Table 3: Recombinant DNA construct for CPEB2B. Snapgene software was used to
generate a transgenic plasmid that could induce the expression of CPEB2B in a model.
In brief, a pKO2.2 plasmid backbone was fused to a genetic sequence synthesized from
ThermoFisher to drive the expression of CPEB2B in vitro. The sequence contained the
cDNA for each of the exons in the CPEB2 mRNA transcript, including exon 3, which
distinguished CPEB2B from CPEB2A.
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CONCLUSIONS
This study has provided us with a glimpse into the mechanism by which HIF1
transcriptional activity is maintained during chronic hypoxia, and what factors are playing
a role in the complex that regulates stress-induced translation of mRNA. Sustained HIF1
expression is a common feature found in pulmonary arterial hypertension and targeting
its expression in patients that are predisposed to chronic hypoxic stress could be
advantageous to their prognosis. All in all, this study has shown us that CPEB2 alternative
splicing plays a critical role in regulating HIF1 and strengthens the possibility that ASOdirected therapies can be used to target hypoxia-induced angiogenesis, and in turn,
vascular remodeling and pulmonary arterial hypertension.
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